Vnitr Lek 2024, 70(5):308-313 | DOI: 10.36290/vnl.2024.061

Percutaneous coronary angioplasty for chronic coronary syndrome: the antithrombotic therapy

Ivo Varvařovský1, Roman Miklík2
1 Kardiologické centrum Agel, Pardubice
2 Kardiocentrum Agel Třinec-Podlesí

Percutaneous coronary angioplasty (PCI) is an established method of treating chronic coronary syndrome, the safety of which is fundamentally increased by properly administered antithrombotic treatment. The actual performance of PCI is ensured by a combination of anticoagulant treatment and acetylsalicylic acid. Platelet P2Y12 receptor inhibitors have been shown to be crucial for the safe use of coronary stents both in the perioperative period and in long-term treatment after PCI. The choice of a P2Y12 inhibitor and the duration of its administration are governed primarily by the risk of bleeding.

Keywords: percutaneous coronary angioplasty (PCI), chronic coronary syndrome (CCS), antithrombotic treatment.

Accepted: August 28, 2024; Published: September 4, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Varvařovský I, Miklík R. Percutaneous coronary angioplasty for chronic coronary syndrome: the antithrombotic therapy. Vnitr Lek. 2024;70(5):308-313. doi: 10.36290/vnl.2024.061.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87165. Go to original source... Go to PubMed...
    2. https://www.uzis.cz/index.php?pg=record & id=8431
    3. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60. Go to original source... Go to PubMed...
    4. Noda T, Nochioka K, Kaikita K. Antithrombotic therapy for stable coronary artery disease and atrial fibrillation in patients with and without revascularisation: the AFIRE trial. EuroIntervention. 2024;20:425-435. Go to original source... Go to PubMed...
    5. Han JK, Hwang D, Yang S. Comparison of 3- to 6-month versus 12-month dual antiplatelet therapy after coronary intervention using the contemporary drug-eluting stents with ultrathin struts: the HOST-IDEA randomized clinical trial. Circulation. 2023;147:1358-68. Go to original source... Go to PubMed...
    6. Condello F, Spaccarotella C, Sorrentino S. Stent thrombosis and restenosis with contemporary drug-eluting stents: predictors and current evidence. J Clin Med. 2023;12:1238. Go to original source... Go to PubMed...
    7. Chen Z, Matsumura M, Mintz GS, et al. Prevalence and impact of neoatherosclerosis on clinical outcomes after percutaneous treatment of second-generation drug-eluting stent restenosis. Circ Cardiovasc Interv. 2022;15:e011693. Go to original source... Go to PubMed...
    8. Lazar FL, Onea HL, Olinic DM. A 2024 scientific update on the clinical performance of drug-coated balloons. AsiaIntervention. 2024;10:15-25. Go to original source... Go to PubMed...
    9. Colombo A, Hall P, Nakamura S. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91:1676-88. Go to original source... Go to PubMed...
    10. Leon MB, Baim DS, Popma JJ. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998;339:1665-71. Go to original source... Go to PubMed...
    11. Widimský P, Moťovská Z, Šimek S. Clopidogrel pre-treatment in stable angina: for all patients 6h before elective coronary angiography or only for angiographically selected pacients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J. 2008;29:1495-503. Go to original source... Go to PubMed...
    12. Luo X, Hou M, He S. Efficacy and safety of concomitant use pf proton pump inhibitors with aspirin-clopidogrel dual antiplatelet therapy in coronary heart disease: a systematic review and meta-analysis. Front Pharmacol 2023;13:1021584. Go to original source... Go to PubMed...
    13. Steg PG, Bhatt DL, Hamm CW. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382:1981-92. Go to original source... Go to PubMed...
    14. Angiolillo DJ, Rollini F, Storey RF. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation. 2017;136:1955-75. Go to original source... Go to PubMed...
    15. Valgimigli M, Bueno H, Byrne RA. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2018;39:213-54. Go to original source... Go to PubMed...
    16. Costa F, van Klaveren D, Feres F. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. J Am Coll Cardiol. 2019;73:741-54. Go to original source... Go to PubMed...
    17. Byrne RA, Rossello X, Coughlan JJ. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720-3826. Go to original source... Go to PubMed...
    18. Kang J, Park KW, Lee H. Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study. Circulation. 2023;147:108-17. Go to original source... Go to PubMed...
    19. Lopes RD, Heizer G, Aronson R. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509-24. Go to original source... Go to PubMed...
    20. Alexander JH, Wojdyla D, Vora A. Risk/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS. Circulation. 2020;141:1618-27. Go to original source... Go to PubMed...
    21. Zhang Y, Zhang X, Dong Q. Duration of dual antiplatelet therapy after implantation of drug-coated balloon. Front Cardiovasc Med. 2021;8:762391. Go to original source... Go to PubMed...
    22. Knuuti J, Wijns W, Saraste A. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407-77. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.